Skip to main
  1. Stocks
  2. Tvardi Therapeutics Inc
  3. Forecast
TVRD

TVRD Stock Forecast & Price Target

TVRD Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 13%
Sell 13%
Strong Sell 0%

Bulls say

Tvardi Therapeutics is attractive fundamentally because its STAT3 franchise has already shown direct human target engagement, with TTI-101 producing an 18% confirmed partial response rate, 53% disease control, and 100% pY-STAT3 reduction in biopsied HCC patients, while the company’s clean safety profile and no dose-limiting toxicities support continued development. The investment case is further strengthened by TTI-109, which delivered equivalent active-moiety exposure, dose-proportional PK, profound immune-cell reductions, and markedly shorter diarrhea duration than TTI-101, suggesting the tolerability issue is being solved without sacrificing pharmacology. Financially, the company held $25 million in cash and short-term investments as of March 31, 2026, with operations funded into 4Q26, while the market capitalization of about $29 million implies near-zero value for the pipeline despite multiple catalysts.

Bears say

Tvardi Therapeutics is fundamentally challenged by a target class that has repeatedly failed in the clinic: direct STAT3 inhibition has faced structural drug-design barriers, poor selectivity, off-target toxicity, and no FDA-approved precedent despite more than two decades of effort. Its latest setback in the Phase 2 REVERT IPF trial, where roughly 88 patients were treated and discontinuation rates reached 56.7% and 62.1% in the TTI-101 arms versus 10.3% for placebo, reinforced tolerability concerns while the unusually shallow placebo decline made efficacy harder to prove. With no approved products, dependence on TTI-101 in HCC and TTI-109, and only $25 million in cash as of March 31, 2026, the company also faces meaningful development, regulatory, and dilution risk.

TVRD has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tvardi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

TVRD Analyst Forecast & Price Prediction

Get the latest TVRD stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TVRD

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tvardi Therapeutics Inc (TVRD) Forecast

Analysts have given TVRD a Buy based on their latest research and market trends.

According to 8 analysts, TVRD has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tvardi Therapeutics Inc (TVRD)


TVRD Analyst Forecast & Price Prediction

Get the latest TVRD stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TVRD

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TVRD stock data and trends